Infective endocarditis and solid organ transplantation: Only worse outcomes during initial transplantation hospitalization - 26/09/21
, Jerome J. Federspiel, MD, PhD c, dRiassunto |
Background |
The epidemiology, and outcome of infective endocarditis (IE) among solid organ transplant (SOT) recipients is unknown.
Methods |
We used data from the 2013-2018 Nationwide Readmissions Database (NRD). IE- and SOT-associated hospitalizations were identified using diagnosis and procedure codes. Outcomes included inpatient mortality, length of stay, and inpatient costs. Adjusted analyses were performed using weighted regression models.
Results |
A total of 99,052 IE-associated hospitalizations, corresponding to a weighted national estimate of 193,164, were included for analysis. Of these, 794 (weighted n = 1,574) were associated with transplant history (SOT-IE). Mortality was not significantly different between SOT-IE and non-SOT-IE (17.2% vs. 15.8%, adjusted relative risk [aRR]: 0.86, 95% confidence interval [CI] [0.71, 1.03]), and fewer SOT-IE patients underwent valve repair or replacement than non-SOT-IE (12.5% vs. 16.2%, aRR 0.82, 95% CI [0.71, 0.95]). We then compared outcomes of patients diagnosed with IE during their index transplant hospitalization (index-SOT-IE) to patients without IE during their transplant hospitalization (index-SOT). Index-SOT-IE occurred most frequently among heart transplant recipients (45.1%), and was associated with greater mortality (27.1% vs. 2.3%, aRR 6.07, 95% CI [3.32, 11.11]).
Conclusion |
Dual diagnosis of SOT and IE was associated with worse outcomes among SOT recipients during index hospitalization, but not overall among patients with IE.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 240
P. 63-72 - Ottobre 2021 Ritorno al numero
Articolo precedente
- Renin–angiotensin–aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system
- Alexander T Sandhu, Shun Kohsaka, Shoutzu Lin, Christopher Y Woo, Mary K. Goldstein, Paul A Heidenreich
- Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials
- Gad Cotter, Beth A. Davison, Christopher Edwards, Stefanie Senger, John R. Teerlink, Faiez Zannad, Olav Wendelboe Nielsen, Marco Metra, Alexandre Mebazaa, Ovidiu Chioncel, Barry H Greenberg, Aldo P Maggioni, Georg Ertl, Naoki Sato, Alain Cohen-Solal
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?